M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

Phase 2

Recruiting

Conditions: Metastatic Malignant Female Reproductive System Neoplasm

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Volume Modulated Arc Therapy

First Posted Date: 2020-08-18

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 108

Registration Number: NCT04516135

Locations: 🇺🇸
OhioHealth, Columbus, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cooper Hospital University, Camden, New Jersey, United States

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Active, not recruiting

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Dual X-ray Absorptiometry

First Posted Date: 2020-08-18

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT04516122

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Myelofibrosis Transformation in Essential Thrombocythemia
Primary Myelofibrosis

Interventions: Biological: Elotuzumab
Other: Questionnaire Administration

First Posted Date: 2020-08-18

Last Posted Date: 2024-06-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04517851

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Brain
Stage IVA Lung Cancer AJCC v8
Metastatic Lung Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Other: Questionnaire Administration
Radiation: Stereotactic Radiosurgery

First Posted Date: 2020-08-17

Last Posted Date: 2024-10-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT04516070

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)

Not Applicable

Conditions: COVID-19 Infection

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2020-08-14

Last Posted Date: 2021-12-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 257

Registration Number: NCT04513990

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Stage IA3 Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8

Interventions: Other: Hafnium Oxide-containing Nanoparticles NBTXR3
Radiation: Radiation Therapy

First Posted Date: 2020-08-10

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04505267

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Acalabrutinib
Biological: Obinutuzumab

First Posted Date: 2020-08-10

Last Posted Date: 2024-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04505254

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic

Recruiting

Conditions: COVID-19 Infection
Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-08-05

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50000

Registration Number: NCT04500600

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Phase 1

Withdrawn

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Alvocidib Hydrochloride
Drug: Decitabine
Drug: Venetoclax

First Posted Date: 2020-07-30

Last Posted Date: 2020-11-12

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04493099

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Phase 1

Recruiting

Conditions: Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Myelodysplastic Syndrome
Recurrent Chronic Myelomonocytic Leukemia
Myeloproliferative Neoplasm
Recurrent Myeloproliferative Neoplasm

Interventions: Drug: Azacitidine
Drug: Quizartinib

First Posted Date: 2020-07-30

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT04493138

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy